You can view 5 more pages before signing in

Monitoring liver function with glitazone therapy

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

This is recommended as (1):

checking liver enzymes prior to the initiation of therapy and then monitoring them every 2 months for the first 12 months of glitazone therapy, and periodically thereafter
if ALT levels are increased to 3x upper limit of normal then there should be a reassessment of the liver enzymes as soon as possible. Glitazone therapy should be discontinued if levels remain > 3x the upper limit of normal

A Drugs and Therapeutics Bulletin review (2) states that 'the drugs are also contraindicated in patients with impaired liver function (i.e. with ALT levels more than 2.5 times the upper limit of normal) or any other signs of liver disease.' The British National Formulary however states that a contraindication to glitazone therapy is hepatic impairment and does not qualify this with respect to liver function tests.

Reference:

CSM/MCA (2001). Current problems in pharmacovigilance, 27, 11.
Drugs and Therapeutics Bulletin (2001), 39 (9), 65-68.

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page